Skip to Content

View Additional Section Content

A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent

For more information on this trial, click the link below.

https://clinicaltrials.gov/ct2/show/NCT03033576?term=s1616&rank=1

Clinical Trial Categories

  • Melanoma
Contact
Carolann Twelves, RN at 215-481-4149

Location

  • Asplundh Cancer Pavilion
    3941 Commerce Ave.
    Willow Grove, PA 19090

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a
Test

215-481-EXAM